It has been previously demonstrated that lipopolysaccharides (LPS) inhibit the viability, migration, adhesion and in vitro angiogenesis of late endothelial progenitor cells (EPCs). However, the mechanisms underlying this LPS-induced impairment of late EPC functional activity are unknown. The aim of the present study was to investigate whether Toll-like receptor 4 (TLR4) is expressed and functional on late EPCs, using late EPCs of 3-5 passages. Cells were deprived of serum for 24 h prior to experiments and incubated with 10 µg/ml LPS for 24 h with or without pretreatment with 2 µg/ml TLR4 signaling inhibitor CLI-095 for 30 min. The viability, migration, adhesion and in vitro angiogenesis, as well as the expression of silent information regulator 1 (SIRT1), in late EPCs were evaluated. Treatment with 10 µg/ml LPS decreased the viability, migration and adhesion abilities, and in vitro angiogenesis of late EPCs. Pretreatment with the TLR4 signaling inhibitor reversed this LPS-induced dysfunction of late EPCs. LPS downregulated the expression of SIRT1 protein, however, blocking TLR4 attenuated the effect of LPS on SIRT1 expression. Therefore, the results of the present study indicate that LPS impaired the functional activity of late EPCs via TLR4, which may be associated with decreased SIRT1 expression.
Introduction
In 1997, Asahara et al (1) isolated endothelial progenitor cells (EPCs) from adult peripheral blood and revealed that EPCs served an important role in the angiogenesis of ischemic tissues. Following this discovery, EPCs have been investigated. EPCs have since been observed in umbilical cord blood, bone marrow and tissue resident niches (2) (3) (4) . In addition, the associations between EPCs, and cardiovascular risk factors and the outcome of cardiovascular diseases have been investigated in depth. Associations between EPCs and lung diseases have also been reported (5) (6) (7) . Previous studies have demonstrated that transplantation of circulating EPCs attenuated lung injury and improved survival in rats with lung injury (8) (9) (10) . These results suggested that EPCs may serve an important role in lung injury repair.
An increasing body of evidence has revealed that EPCs can be divided into two populations: Early and late EPCs (11, 12) . Early EPCs have a spindle-like shape and appear in culture following 3-5 days, gradually disappearing in 4 weeks. They also have a low proliferative capacity and promote angiogenesis via the secretion of cytokines. By contrast, late EPCs, which have a cobblestone shape, appear following 1-4 weeks following plating and exhibit a high proliferative activity, providing a number of endothelial cells that contribute to the repair of damaged endothelium and enhance angiogenesis.
Unlike early EPCs, late EPCs have not been studied in great detail. The authors previously demonstrated that lipopolysaccharide (LPS) inhibited the viability, migration, adhesion and in vitro angiogenesis of late EPCs (13) . However, the mechanisms by which LPS induces the impairment of late EPC functional activity remain unknown. A previous study revealed that LPS can exert proinflammatory effects via the toll-like receptor 4 (TLR4) signaling pathway and also decreased the expression of silent information regulator 1 (SIRT1), which in turn exerts anti-inflammatory effects against cellular injury (14) . It is currently unclear whether the TLR4 signaling pathway is involved in the LPS-induced impairment of late EPC functional activity thus, the aim of the present study was to investigate whether TLR4 is expressed and functional on late EPCs. Membranes were blocked for 1 h at room temperature with 5% non-fat milk in TBS containing 0.05% Tween-20 (TBST) and incubated with the polyclonal rabbit anti-TLR4 antibody (1:500) at 4˚C overnight, followed by 1 h incubation at room temperature with a horseradish peroxidase-conjugated secondary goat polyclonal anti-rabbit antibody (cat. no. A0545; 1:1,000; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The protein bands were visualized using SuperSignal West Pico Chemiluminescent Substrate (cat. no. 34079; Thermo Fisher Scientific, Inc.).
Materials and methods

Isolation
RT-PCR.
To investigate the expression of TLR4 mRNA, total RNA was extracted from late EPCs using TRIzol according to the method described by the manufacturer (Thermo Fisher Scientific, Inc.). Total RNA (200 ng) was reverse transcribed and amplified with RNA PCR kit (cat. no. DRR019A; Takara Bio, Inc., Otsu, Japan) using following primers: TLR-4, forward 5'-GTT CTC TAC TCT TGT GCT TGT-3' and reverse, 5'-TGT TAA TCT CTT ACT GTG CCT AAT-3' . The thermocycling conditions were as follows: Denaturation at 96˚C for 5 min; followed by 30 cycles of 96˚C for 45 sec, 57˚C for 30 sec and 72˚C for 30 sec; and then 1 cycle at 72˚C for 10 min. The amplification products were electrophoresed on 1% agarose gel in Tris base-boric acid-EDTA buffer solution containing the GoldView™ nucleic acid stain and visualized using UV transilluminator apparatus.
Cell treatments. Late EPCs from passages 3-5 were used for subsequent experiments and were divided into the following groups: Control, CLI-095 only treatment, LPS only treatment and LPS+CLI-095 treatment. Cells were deprived of serum for 24 h at 37˚C prior to experiments, then cells in the treatment groups were pretreated with or without 2 µg/ml of the TLR4 signaling inhibitor CLI-095 (Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min and then further incubated with or without 10 µg/ml LPS (Sigma-Aldrich; Merck KGaA) for 24 h at 37˚C.
Effects of CLI-095 on functional activity of late EPCs.
The functional activity of late EPCs were determined according to previously described methods (13, (15) (16) (17) .
MTT assay. The effect of CLI-095 on the viability of late EPCs was evaluated with an MTT assay. Late EPCs (1x10 4 ) were digested, cultured in 96-well culture plates (150 µl/well), and then treated with either LPS (10 µg/ml) or CLI-095 (2 µg/ml). Following culture for 24 h, late EPCs were supplemented with 100 µl EGM-2 containing MTT (0.5 g/l; Sigma-Aldrich; Merck KGaA) and incubated for a further 4 h at 37˚C. Then, the supernatant was aspirated and 150 µl dimethyl sulfoxide was added. The late EPC preparation was shaken for 10 min, prior to analysis of the optical density value measured at 490 nm.
Boyden chamber assay. The migration activity of late EPCs was assessed via a Boyden chamber assay. EGM-2 (100 µl) containing 2x10 4 EPCs was added to the upper chamber of a transwell cell culture insert (8 µm pore size; BD Biosciences, Franklin Lakes, NJ, USA). EGM-2 (0.5 ml) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) was placed in the lower chamber. Following incubation for 24 h at 37˚C, the upper side of the membrane was wiped gently with a cotton ball. Then, the membranes were washed with PBS and fixed with 100% methanol for 20 min at room temperature. For quantification, cells were stained with 4' ,6-diamidino-2-phenylindole solution for 20 min at room temperature. Cells migrating into the lower chamber were counted by eye using light microscopy in 5 random high-power (magnification, x100) microscopic fields, and the average numbers of cells/field were determined.
Cell adhesion assay. The adhesive capacity was determined using a cell adhesion assay. Late EPCs (5x10 3 ) in 50 µl EGM-2 were replated onto a 96-well plate and incubated for 30 min at 37˚C. The non-adherent cells were removed and the number of adherent cells was counted by eye using light microscopy.
Capillary formation. In vitro vasculogenesis capacity was evaluated by analyzing the capillary formation in Matrigel (BD Biosciences). Late EPCs (1x10 4 ) suspended in 100 µl EGM-2 were plated onto a 96-well plate preincubated with Matrigel diluted with EGM-2 (1:1). Following incubation for 3-9 h at 37˚C, tube formation was observed under a light microscope (one field in one well of 96-well plate under light microscopy at 40x magnification) and the length of the capillary tubes in a random field of each well was recorded.
Effects of CLI-095 on the expression of SIRT1 on late EPCs.
The expression of the SIRT1 protein was analyzed following the methods described in the aforementioned western blotting section. Proteins (15 µg/lane) were separated by SDS-PAGE on 10% gels and transferred to a PVDF membrane, which again was blocked with 5% non-fat milk and TBST. Membranes were incubated with a polyclonal rabbit anti-SIRT1 antibody (cat. no. sc-15404; 1:1,000; Santa Cruz Biotechnology, Inc.) overnight at 4˚C, followed by a 1 h incubation at room temperature with a secondary goat polyclonal anti-rabbit antibody (cat. no. A0545; 1:1,000; Sigma-Aldrich; Merck KGaA). β-actin (anti-β-actin antibody, cat. no. sc-130656; 1:1,000; Santa Cruz Biotechnology, Inc.) was used as an internal control. The protein bands were visualized with an ECL kit (Thermo Fisher Scientific, Inc.) and images were analyzed by Quantity One version 4.62 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Statistical analysis.
All data are presented as the mean ± standard deviation. Differences between group were assessed by one-way analysis of variance, followed by Tukey's multiple comparison tests using SPSS version 16.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
TLR4 is expressed on late EPCs.
To investigate the expression of TLR4, late EPCs were incubated with TLR4 antibodies. As demonstrated in Fig. 1A , immunostaining demonstrated that late EPCs expressed TLR4. In addition, the expression of TLR4 protein and mRNA was further verified by western blotting (Fig. 1B) and RT-PCR (Fig. 1C) , respectively.
Effect of CLI-095 on late EPC viability.
The effect of CLI-095 on late EPC viability was evaluated using an MTT assay (Fig. 2) . Treatment with 10 µg/ml LPS significantly decreased late EPC viability. To investigate the role of TLR4 in late EPC viability, the effect of the TLR4 signaling inhibitor CLI-095 (2 µg/ml) on late EPC viability was investigated. Pretreatment with CLI-095 alone for 30 min did not affect viability when compared with the control. However, when compared with LPS only treatment, pretreatment with CLI-095 was able to reverse the decrease in viability induced by LPS (Fig. 2) .
Effect of CLI-095 on late EPC migration.
The effect of CLI-095 on late EPCs migration was analyzed using a modified Boyden chamber assay. When compared with the control group, the migratory activity of late EPCs incubated with 10 µg/ml LPS was significantly decreased (Fig. 3) . Pretreatment with 2 µg/ml CLI-095 only for 30 min did not affect migration; however, when combined with treatment with LPS it significantly inhibited the decrease in LPS-induced late EPC migration (Fig. 3) .
Effect of CLI-095 on late EPC adhesiveness.
The effect of CLI-095 on the adhesion of late EPCs was evaluated using an adhesion assay. Treatment with 10 µg/ml LPS only significantly impaired adhesion, however, combined treatment with 2 µg/ml CLI-095 attenuated this effect (Fig. 4) . CLI-095 pretreatment alone did not significantly alter adhesion (Fig. 4) .
Effect of the TLR4 inhibitor CLI-095 on late EPC vasculo-
genesis. An in vitro cell adhesion assay was used to evaluate the effect of CLI-095 on late EPC vasculogenesis. Following plating of late EPCs on to a basement membrane matrix, tube formation was observed. Incubation with 10 µg/ml LPS only significantly decreased tube length; however, CLI-095 pretreatment (2 µg/ml) alone did not significantly alter tube length (Fig. 5 ). Combined treatment with LPS and CLI-095 increased the tube length when compared to LPS treatment only, thereby attenuating the LPS-induced effects (Fig. 5) .
Effect of the TLR4 inhibitor CLI-095 on the expression of SIRT1.
To investigate the potential mechanisms underlying the effects of LPS treatment, the present study assessed the effect of LPS on SIRT1 expression in late EPCs. As demonstrated in Fig. 6 , 10 µg/ml LPS significantly downregulated the expression of SIRT1 protein. Pretreatment with 2 µg/ml CLI-095 reversed this LPS-induced decrease in SIRT1 expression to an extent.
Discussion
The results of the present study have demonstrated that TLR4 is expressed on late EPCs. In addition, LPS downregulated the expression of SIRT1 via TLR4 and the TLR4 signaling inhibitor CLI-095 attenuated the LPS-induced dysfunction of late EPCs.
TLRs are evolutionarily-conserved protein receptors that serve an important role in the recognition of pathogen-associated molecular patterns. An increasing body of evidence has revealed that TLRs are associated with a number of pathophysiological processes, including cancer, and autoimmune, infectious and cardiovascular diseases (18, 19) . Since TLRs were first described in 1997 (20) , 11 TLRs and their respective ligands have subsequently been identified in humans, of which, TLR4 is by far the most intensively studied and the best functionally characterized. To date, it has been reported that TLR4 is expressed on various cell types including hepatocytes and, epithelial, endothelial and smooth muscle cells. As a cellular receptor for endotoxin receptors, TLR4 serves a key role in the recognition of Gram-negative bacterial components (LPS) and in LPS-induced acute lung injury. However, a body of evidence has demonstrated that several other receptors and the TLR4-independent pathway may also be involved in the LPS-associated effects (21) (22) (23) (24) .
The authors previously demonstrated that LPS impaired the viability, migration, adhesion and in vitro vasculogenesis capacity of late EPCs (13) . On this basis, the present study revealed that inhibition of TLR4 signaling can reverse this impairment of functional activity in late EPCs, which suggested that TLR4 signaling pathways may be involved in the LPS-induced dysfunction of late EPCs.
LPS activates two distinct intracellular signaling pathways via TLR4 (25) : The myeloid differentiation primary response gene 88-dependent and TIR-domain-containing adapter-inducing interferon-β-dependent signaling pathways. However, the mechanism underlying the action of LPS on late EPCs remains to be determined. SIRT1, the most well-studied protein of the sirtuin family, has been shown to mediate the pathogenesis of a variety of chronic diseases, including obesity (26) , diabetes (27) and cardiovascular diseases (28) . Recent studies have revealed that SIRT1 can exhibit pronounced anti-inflammatory properties (29, 30) . It has been previously established that LPS decreased the expression of SIRT1 and increased the levels of TNF-α and interleukin-6 (14) . In addition, TNF-α reduced SIRT1 expression in endothelial cells (31) and human chondrocytes (32); however, resveratrol (a known SIRT1 activator) suppressed this effect. The dysregulation of SIRT1 promoted the nicotinamide adenine dinucleotide phosphate oxidase-dependent production of reactive oxygen species and impaired endothelial function (33) . By contrast, activation of SIRT1 by resveratrol increased vascular oxidative stress resistance (34) and protected endothelial cells (35) and cardiomyocytes (36) against oxidative stress. In the present study, LPS downregulated the expression of SIRT1, which was reversed by inhibiting TLR4 signaling. These results suggest that LPS may impair late EPCs, at least in part, by activating TLR4 and decreasing the expression of SIRT1. However, whether activation of SIRT1 by resveratrol can protect late EPCs against LPS-induced injury requires further investigation.
A few limitations were apparent in the present study. Recent studies have demonstrated that LPS can exert its effects though TLR4-dependent and -independent pathways (22, 37) . However, only the TLR4-dependent pathway was investigated in the present study. Thus, whether the TLR4-independent pathway is also involved requires further elucidation. Although LPS decreased the expression of SIRT1 via TLR4, the mechanism underlying how TLR4 activation affected SIRT1 expression was not determined. The effects of LPS on late EPCs in vivo may be different from those observed in vitro.
In conclusion, the present study demonstrated that LPS impaired the functional activity of late EPCs via TLR4, which may be associated with a decrease in the expression of SIRT1.
